Applied Optoelectronics to Present at the Rosenblatt 4th Annual Technology Summit: The Age of AI
SUGAR LAND, Texas, June 03, 2024 (GLOBE NEWSWIRE) — Applied Optoelectronics, Inc. (NASDAQ: AAOI), a leading provider of fiber-optic access […]
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage […]
Locafy to Participate in the “Charting the Course: Navigating the Intersection of TMT and Business in the AI Era” Conference Presented by Maxim Group LLC on Tuesday, June 4th at 4:30 p.m. ET
PERTH, Australia, June 03, 2024 (GLOBE NEWSWIRE) — Locafy Limited (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a globally recognized […]
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel […]
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical […]
Lavoro Reports Fiscal Third Quarter 2024 Earnings Results¹
3Q24 revenue grew 6% to $514.2 million. Growth was driven by continued market share gains and volume growth, which mitigated […]
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 3, 2024, 10.05pm CET / 4.05pm [...]
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company […]
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with […]
Dave Extends its Partnership with Drew League, LA’s Pro-Am Basketball League
LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) — Dave (NASDAQ: DAVE), one of the nation’s leading neobanks, announced an extension […]
